Will Johnson & Johnson Undercut Merck’s Bid to Buy Schering-Plough?
This article was originally published in The Pink Sheet Daily
Executive Summary
A 1998 change-of-control provision tied to Remicade complicates Merck’s attempted mega-merger.
You may also be interested in...
J&J Celebrates Simponi Approval With Schering – For Now
As Schering waits to see if partner J&J will challenge Merck merger, FDA clears once-monthly follow-on to Remicade.
J&J Celebrates Simponi Approval With Schering – For Now
As Schering waits to see if partner J&J will challenge Merck merger, FDA clears once-monthly follow-on to Remicade.
Merck Is Mercury, Schering Is Saturn; Is J&J The Death Star?
SEC documents reveal Schering-Plough will owe Merck $1.5 billion if their proposed deal collapses. The earthly break-up fee could spur J&J to make a counter-offer.